Janux Therapeutics Inc (JANX) - Net Assets
Based on the latest financial reports, Janux Therapeutics Inc (JANX) has net assets worth $976.55 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.02 Billion) and total liabilities ($48.21 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Janux Therapeutics Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $976.55 Million |
| % of Total Assets | 95.3% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 94.42 |
Janux Therapeutics Inc - Net Assets Trend (2019–2024)
This chart illustrates how Janux Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Janux Therapeutics Inc for the complete picture of this company's asset base.
Annual Net Assets for Janux Therapeutics Inc (2019–2024)
The table below shows the annual net assets of Janux Therapeutics Inc from 2019 to 2024. For live valuation and market cap data, see Janux Therapeutics Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.02 Billion | +197.02% |
| 2023-12-31 | $344.35 Million | +7.36% |
| 2022-12-31 | $320.74 Million | -12.44% |
| 2021-12-31 | $366.33 Million | +2602.58% |
| 2020-12-31 | $-14.64 Million | -84.26% |
| 2019-12-31 | $-7.94 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Janux Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 22980200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $59.00K | 0.01% |
| Other Comprehensive Income | $2.16 Million | 0.21% |
| Other Components | $1.26 Billion | 123.03% |
| Total Equity | $1.02 Billion | 100.00% |
Janux Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Janux Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Qingdao Hiron Commercial Cold Chain Co Ltd
SHG:603187
|
$790.50 Million |
|
Anhui Genuine New Materials Co Ltd
SHG:603429
|
$790.51 Million |
|
Shenzhen Longtech Smart Control Co. Ltd.
SHE:300916
|
$790.97 Million |
|
Semen Indonesia Persero Tbk
JK:SMGR
|
$791.23 Million |
|
Wuxi Xuelang Environmental Technology Co Ltd
SHE:300385
|
$790.23 Million |
|
Guangdong Banbao Toy Co Ltd
SHG:603398
|
$790.02 Million |
|
Mishra Dhatu Nigam Limited
NSE:MIDHANI
|
$789.94 Million |
|
Hebei Huijin Electromechanical Co Ltd
SHE:300368
|
$789.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Janux Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 344,349,000 to 1,022,781,000, a change of 678,432,000 (197.0%).
- Net loss of 68,994,000 reduced equity.
- New share issuances of 698,267,000 increased equity.
- Other comprehensive income increased equity by 1,498,000.
- Other factors increased equity by 47,661,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-68.99 Million | -6.75% |
| Share Issuances | $698.27 Million | +68.27% |
| Other Comprehensive Income | $1.50 Million | +0.15% |
| Other Changes | $47.66 Million | +4.66% |
| Total Change | $- | 197.02% |
Book Value vs Market Value Analysis
This analysis compares Janux Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.75x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.19 | $14.34 | x |
| 2020-12-31 | $-0.35 | $14.34 | x |
| 2021-12-31 | $8.88 | $14.34 | x |
| 2022-12-31 | $7.73 | $14.34 | x |
| 2023-12-31 | $7.82 | $14.34 | x |
| 2024-12-31 | $19.03 | $14.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Janux Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -6.75%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -651.62%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.04x
- Recent ROE (-6.75%) is above the historical average (-8.24%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.44 Million |
| 2020 | 0.00% | -1785.26% | 0.02x | 0.00x | $-5.32 Million |
| 2021 | -8.89% | -895.22% | 0.01x | 1.04x | $-69.19 Million |
| 2022 | -16.88% | -628.82% | 0.02x | 1.13x | $-86.23 Million |
| 2023 | -16.93% | -721.18% | 0.02x | 1.10x | $-92.73 Million |
| 2024 | -6.75% | -651.62% | 0.01x | 1.04x | $-171.27 Million |
Industry Comparison
This section compares Janux Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Janux Therapeutics Inc (JANX) | $976.55 Million | 0.00% | 0.05x | $790.34 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment o… Read more